FDA approves simplified monitoring for Travere's FILSPARI kidney drug
Tweet Send to a Friend
The U.S. Food and Drug Administration approved updated Risk Evaluation and Mitigation Strategy labeling for Travere Therapeutics Inc.'s (NASDAQ: TVTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


